Pulmonary Arterial Hypertension (PAH) Market
Current Industry Status, Target Audience,Top
Key Players
Pulmonary hypertension or PH is a condition in which the blood pressure rises in the
pulmonary artery, vein, or capillaries (collectively known as lung vasculature), which might
lead to shortness of breath, fainting, leg swelling, and dizziness, among others. Pulmonary
hypertension may be a relentless disease with a noticeable reduction in exercise tolerance.
Pulmonary arterial hypertension or PAH indicates that the patient has high blood pressure in
arteries that carry blood from the heart to the lungs. With PAH, the arteries in the lungs
become thin or get blocked resulting into irregular blood flow. Since the flow of blood is
hindered, it becomes hard for the blood to flow evenly thereby, increasing the blood pressure
in the patient. In layman terms, it means that the heart works harder to pump blood. It may
lead to weakening of the heart muscles after a certain period of time. Ultimately, pulmonary
arterial hypertension may cause heart failure.
For In depth Information Get Sample Copy of this Report @
https://www.coherentmarketinsights.com/insight/request-sample/203
Based on the reports gathered from a variety of sources, including CDC (Centers for Disease
Control and Prevention) and WHO (World Health Organization), the global prevalence of
pulmonary arterial hypertension is projected to be 100,000 – 200,000, that is about 15 - 50
patients per million of the population. Even though, the treatment available for pulmonary
arterial hypertension is rather limited, various treatment options are available to decrease
symptoms, slow down disease progression, and improve the quality of life. Endothelin receptor
antagonists or ERAs, phosphodiesterase-5 (PDE-5) inhibitors and Prostacyclin and prostacyclin
analogs are some of the widely prescribed drug classes used for treatment of the disease.
Lately, a new drug class known as the soluble guanylate cyclase or sGC stimulators has been
recognized to be effective in treating people with PAH.
On the contrary, the expiry of patents of major pulmonary arterial hypertension drugs such as
Letairis, Tracleer, Tyvaso, and Adcirca is projected to pose a challenge for the growth of the
market, as the generic versions of these drugs will be sold at 70% to 80% lower prices than